Ascendis Health Limited

ASC

ZAE000185005

Pharmaceuticals

End-of-day quote Johannesburg S.E. Other stock markets 06:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
0.81 ^ZAR	0.00%		+1.25%	+3.85%

Mar. 29	Ascendis Health Seeks Acquisitions	CI
Mar. 28	Ascendis Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Ascendis Health Limited Announces Resignation of Gary Shayne as A Non-Executive Director

June 05, 2022

Ascendis Health Limited announced that Gary Shayne has resigned as a non-executive director of Ascendis Health with immediate effect. The board of directors of Ascendis Health thanks Gary for his contributions during his tenure and wishes him well in his future endeavours.

Latest news about Ascendis Health Limited

Ascendis Health Seeks Acquisitions	Mar. 28	CI
Ascendis Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 28	CI
Ascendis Health Limited Provides Earnings Guidance for the Six Months Ended 31 December 2023	Mar. 26	CI
Ascendis Health Limited Announces Board Changes	Mar. 25	CI
Ascendis Health Limited Announces Lawrence Mulaudzi Not Available for Re-Election as Director	Nov. 29	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29	CI
Ascendis Health Limited Appoints Joseph Fine as Company Secretary	23-09-27	CI
Ascendis Health Flags Drop in FY23 EPS	23-09-26	MT
Ascendis Health Limited Provides Earnings Guidance for the Year Ended 30 June 2023	23-09-26	CI
Ascendis Health Advances Cost-cutting Program With New Auditor	23-04-06	MT
Ascendis Health Books Lower Fiscal H1 Attributable Profit	23-03-27	MT
Ascendis Health Terminates PricewaterhouseCoopers as Auditor	23-03-20	MT
South African Stocks End Tumultuous Week in the Red	23-03-17	MT
Ascendis Health Flags Lower EPS in Fiscal H1	23-03-17	MT
Ascendis Health Limited Appoints Bharti Harie as Chairman of the Board	22-12-08	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Ascendis Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Transcript : Ascendis Health Limited, 2022 Earnings Call, Sep 28, 2022	22-09-28
Ascendis Health Limited Auditor Raises 'Going Concern' Doubt	22-09-26	CI
Ascendis Health Limited Announces Resignation of Richard Dawes an Independent Non-Executive Director	22-06-27	CI
Pharma-Q Holdings Ltd. and Imperial Logistics Limited cancelled the acquisition of Medicine Developers International/Pharmachem Pharmaceuticals/Alliance Pharma/Ascendis Pharma from Ascendis Health Limited.	22-06-26	CI
Ascendis Health Limited Announces Board Changes	22-06-13	CI
Ascendis Health Limited Announces Resignation of Gary Shayne as A Non-Executive Director	22-06-05	CI
Ascendis Health Limited Appoints Riyas Fadal as Chief Operating Officer	22-05-03	CI
Ascendis Health Seeks Acquisitions	22-02-18	CI

Chart Ascendis Health Limited

Duration

Period

More charts

Company Profile

Ascendis Health Limited specializes in developing, manufacturing and marketing care and health products. Net sales break down by family of products as follows: - pharmaceutical products (61.3%): primarily prescription drugs. The group also provides medical devices used in the radiology and surgery fields; - consumer products (31%): OTC medicines, vitamins and minerals, homeopathic products, ayurvedic products, sports nutrition products, functional foods, etc.; - care products for plants and animals (7.7%). Net sales are distributed geographically as follows: South Africa (71.3%), Cyprus (16%) and Romania (12.7%).

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASCENDIS HEALTH LIMITED	+3.85%	27.44M
ELI LILLY AND COMPANY	+30.75%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.57%	361B
MERCK & CO., INC.	+19.78%	330B
ABBVIE INC.	+3.75%	283B
ASTRAZENECA PLC	+16.70%	239B
NOVARTIS AG	+8.78%	204B
ROCHE HOLDING AG	-7.93%	198B
AMGEN INC.	+8.09%	168B

Other Pharmaceuticals